Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society

Abstract

After a 1-y absence due to the coronavirus disease 2019 pandemic, the 26th Annual Congress of the International Liver Transplantation Society was held from May 15 to 18, 2021, in a virtual format. Clinicians and researchers from all over the world came together to share their knowledge on all the aspects of liver transplantation (LT). Apart from a focus on LT in times of coronavirus disease 2019, featured topics of this year’s conference included infectious diseases in LT, living donation, machine perfusion, oncology, predictive scoring systems and updates in anesthesia/critical care, immunology, radiology, pathology, and pediatrics. This report presents highlights from invited lectures and a review of the select abstracts. The aim of this report, generated by the Vanguard Committee of International Liver Transplantation Society, is to provide a summary of the most recent developments in clinical practice and research in LT.

HBV and HCV Infection Prophylaxis in Liver Transplant Recipients

“…Although disease disease-free patient is the targeted patient for transplant, there a critically ill patients on the transplant list who have decompensated cirrhosis, and the antiviral therapy is not suitable for them, so it would be a lot more beneficial to postpone treatment until after the transplant [64]. Furthermore, patients with child C cirrhosis have a lower response to antiviral therapy so this implies there is a higher risk of resistance to the antivirals.…”